N/A
N=1,112
A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.
Renal Cell Cancer · Renal Cell Carcinoma · Cancer of Kidney · Cancer of the Kidney · Kidney Cancer
Bottom Line
View on ClinicalTrials.gov: NCT05363072 ↗Enrolled (actual)
1,112
Serious AEs
—
Results posted
Oct 2024
Primary outcome: Primary: Number of Participants According to Co-Diagnoses Before Index — 139; 45; 41; 26 Participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Pfizer
- Primary completion
- Jun 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants According to Co-Diagnoses Before Index |
139; 45; 41; 26; 22; 17 | — |
| PRIMARY Number of Participants According to Co-Diagnoses After Index |
144; 32; 28; 28; 15; 15 | — |
| PRIMARY Body Mass Index (BMI) |
27.3; 25.1; 26.5 | — |
| PRIMARY Mean Outpatient Visits and Emergent Room Visits Per Patient Year |
29.37; 19.29; 10.07; 0.28; 0.15; 0.14 | — |
| PRIMARY Mean Number of Hospitalizations Per Patient Year |
1.25; 0.55; 0.7 | — |
| PRIMARY Mean Number of Procedures and Surgeries Per Patient Year |
10.82; 0.77 | — |
| PRIMARY Number of Participants According to Treatment |
25; 8; 5; 24; 129; 21 | — |
| PRIMARY Number of Participants According to Treatment Per Treatment Line Between 2010 to 2017 |
0; 19; 86; 18; 5; 12 | — |
| PRIMARY Number of Participants According to Treatment Per Treatment Line Between 2018 to 2021 |
25; 8; 0; 5; 43; 19 | — |
| PRIMARY Mean Number of Laboratory Days Per Patient Year |
21.85 | — |
| PRIMARY Mean Number of Laboratory Days Per Patient Year Stratified by International Metastatic Database Consortium (IMDC) Risk Category |
21.46; 20.26; 28.26; 19.71 | — |
| PRIMARY Number of Participants Classified According to Karnofsky Performance Status (KPS) Stratified by IMDC Risk Category |
0; 0; 8; 0; 0; 17 | — |
| PRIMARY Number of Participants Classified According to Pathological Diagnosis (PAD) Histology |
41; 597; 27; 105; 0; 342 | — |
Summary
The purpose of the study is to find out how patients with advanced kidney cancer have been treated in the hospital district of Southwest Finland over time.
Eligibility Criteria
Inclusion Criteria
For the characteristic group:
- Diagnosis of renal cell carcinoma (International Classification of Diseases 10th revision [ICD]-10:64) during 01 January 2010 and 31 December 2021
For the mRCC group:
- ICD-10 diagnosis code for metastasis (C77*-C79*), or
- American Joint Committee on Cancer (AJCC) stage 4, or AJCC stage data potentially not available for all patients
- Visit to oncologist (specialty code 65) with RCC as main diagnosis, or In Finland, the ICD-10 codes for metastatic disease are rarely used. In contrast, RCC patients visit oncologist, when and only when disease metastasises and therefore, the visit can be used as a proxy to a metastatic disease
- Initiation of treatment for mRCC
Exclusion Criteria
For the characteristic group:
- Prevalent mRCC patients (i.e. diagnosis of metastatic RCC before 01 January 2010)
- Prevalent mRCC patients (i.e. diagnosis of RCC before 01 January 2010) if there is no records of metastatic disease during 2010-2021
For the mRCC group:
- Prevalent patients with mRCC (i.e. diagnosis of metastatic RCC before 01 January 2010)
- Patients without treatment for mRCC
Data sourced from ClinicalTrials.gov (NCT05363072). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.